Proteomics of Papillary Thyroid Carcinoma

Papillary Thyroid Carcinoma Clinical Trial

Official title:

Differences Protein Expression in Papillary Thyroid Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02814032
• Other study ID #: AHInnerMongolia-Thyroid-02
• Status: Recruiting
• Start date: June 2016
• Est. completion date: June 2024

Study information

• Verified date: July 2023
• Source: The Affiliated Hospital of Inner Mongolia Medical University
• Contact: Shan Jin, PhD
• Phone: +86-15849338280
• Email: jinshangood[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become the malignant neoplasm of fastest growing incidence rate. More than 85% thyroid carcinoma is papillary thyroid carcinoma. Cervical lymph node metastasis is common in papillary thyroid carcinoma patients. This study aim to reveal protein expression differences between papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis.

Description:

1. Object: Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer.

2. Clinical information, examination data: Information is obtained from medical record abstraction.

3. Samples: Fresh frozen thyroid tissues from each sample group(normal histology, benign disease, papillary thyroid carcinoma with cervical lymph node metastasis, papillary thyroid carcinoma without cervical lymph node metastasis ).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: June 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Newly diagnosed papillary thyroid carcinoma.

• Undergo thyroidectomy according to the China thyroid association guidelines forthe Management of thyroid nodule and thyroid cancer.

Exclusion Criteria:

• Current substance abuse/dependence.

• Daily tobacco and alcohol use.

• Whole neck irradiation or surgery.

• Prior cancer diagnosis or chemotherapy treatment.

• Active autoimmune disorder.

• Uncontrolled allergic condition or asthma.

• Chronic use of oral steroid medication.

• Hormone therapy (estrogen, progestin compounds).

Related Conditions & MeSH terms

• Carcinoma
• Papillary Thyroid Carcinoma
• Thyroid Cancer, Papillary
• Thyroid Diseases
• Thyroid Neoplasms

Locations

Country	Name	City	State
China	Shan Jin	Hohhot	Inner Mongolia

Sponsors (1)

Lead Sponsor	Collaborator
The Affiliated Hospital of Inner Mongolia Medical University

Country where clinical trial is conducted

China, 

References & Publications (4)

Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog. 2006 Aug;45(8):613-26. doi: 10.1002/mc.20193. — View Citation

Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am. 2007 Sep;36(3):707-35, vi. doi: 10.1016/j.ecl.2007.04.009. — View Citation

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020. — View Citation

Sofiadis A, Becker S, Hellman U, Hultin-Rosenberg L, Dinets A, Hulchiy M, Zedenius J, Wallin G, Foukakis T, Hoog A, Auer G, Lehtio J, Larsson C. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol. 2012 Apr;166(4):657-67. doi: 10.1530/EJE-11-0856. Epub 2012 Jan 24. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	differences in protein expression		6 months